CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have…
China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…
Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…